Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY8931 in healthy participants
NCT07281703Phase 1Recruiting
- Sponsor
- Newsoara Biopharma
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD), asthma and chronic obstructive pulmonary disease (COPD) comparing HY8931 Arm with Placebo Arm (2 arms). Primary endpoint: Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0 at Day 90. Started Jan 2026; status: recruiting.
02
Drugs
HY8931
03
Conditions
inflammatory bowel disease (IBD)asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07281703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281703.